Tufts researchers reported new ways to expand bacterial spores beyond traditional vaccine concepts, using engineered spores as catalysts for chemical reactions and other biomanufacturing applications. The work focuses on identifying new protein targets that can be harnessed to drive enzyme activity and enable vaccine-related strategies.